îāļāđāļāļŦāļē
îž
î
āļĨāđāļāļāļāļīāļ
îāļāđāļāļŦāļē
î
EyePoint Pharmaceuticals Inc
EYPTîāđāļāļīāđāļĄāļĨāļāđāļāļĢāļēāļĒāļāļēāļĢāļāļīāļāļāļēāļĄ
4.250USD
+0.020+0.47%
āļāļīāļÂ 09-11 16:00ïžETïž
361.17MāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ EyePoint Pharmaceuticals Inc āļāļĢāļīāļĐāļąāļ
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Companyâs lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Companyâs other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Inc āđāļāļĢāđāļāļĨāđ
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļEYPT
āļāļ·āđāļāļāļĢāļīāļĐāļąāļEyePoint Pharmaceuticals Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 27, 2005
āļāļĩāļāļĩāđāļDuker (Jay S)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ165
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJan 27
āļāļĩāđāļāļĒāļđāđ480 Pleasant Street, Suite C400
āđāļĄāļ·āļāļWATERTOWN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02472
āđāļāļĢāļĻāļąāļāļāđ16179265000
āđāļ§āđāļāđāļāļāđhttps://eyepointpharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļEYPT
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 27, 2005
āļāļĩāļāļĩāđāļDuker (Jay S)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ EyePoint Pharmaceuticals Inc
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
Ms. Wendy F. DiCicco, CPA
Ms. Wendy F. DiCicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
137.46K
+21.85%
Ms. Wendy F. DiCicco, CPA
Ms. Wendy F. DiCicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
137.46K
+21.85%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
āļāļģāļāļēāļĄāļāļĩāđāļāļāļāđāļāļĒ
āđāļāļĢāļāļ·āļāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ EyePoint Pharmaceuticals Inc?
îāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ EyePoint Pharmaceuticals Inc āđāļāđāđāļāđ: Dr. Jay S. Duker, M.D.
āļĄāļĩāļāļĩāđāļŠāļāļēāļāļąāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ EyePoint Pharmaceuticals Inc (EYPT)?
îāļ āļ§āļąāļāļāļĩāđ 2026Q1 āļĄāļĩāļŠāļāļēāļāļąāļāļāļģāļāļ§āļ 381 āđāļŦāđāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ EyePoint Pharmaceuticals Inc āđāļāļĒāļĄāļĩāļĄāļđāļĨāļāđāļēāļĢāļ§āļĄāļāļĢāļ°āļĄāļēāļ 88.53M āļāļīāļāđāļāđāļ 105.59% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ āđāļĄāļ·āđāļāđāļāļĩāļĒāļāļāļąāļāļ§āļąāļāļāļĩāđ 2025Q4 āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļāđāļāđāđāļāļīāđāļĄāļāļķāđāļ -2754490.00
āđāļŦāļĨāđāļāļĢāļēāļĒāđāļāđāļŦāļĨāļąāļāļāļāļ EyePoint Pharmaceuticals Inc āļāļ·āļāļāļ°āđāļĢ?
îāđāļĄāļ·āđāļāļ§āļąāļāļāļĩāđ 2026Q1 āļāļļāļĢāļāļīāļāļāđāļēāļ YUTIQ āļŠāļĢāđāļēāļāļĢāļēāļĒāđāļāđāļŠāļđāļāļŠāļļāļāđāļŦāđāļāļąāļ EyePoint Pharmaceuticals Inc āļāļīāļāđāļāđāļāļĄāļđāļĨāļāđāļē 1.60M āđāļĨāļ°āļāļīāļāđāļāđāļ 5.10% āļāļāļāļĢāļēāļĒāđāļāđāļĢāļ§āļĄ